Active HS Clinical Trials
Updated weekly. Includes recruiting and active trials with eligibility highlights. Always discuss trial participation with your physician.
Currently Recruiting (1)
Sonelokimab Phase 2 - MoonLake Immunotherapeutics
MoonLake Immunotherapeutics
Why it matters: Patients with moderate-to-severe HS who have not responded to TNF inhibitors or are biologic-naïve and interested in a next-generation IL-17 approach.
Active / Results Posted (4)
STOP-HS - Povorcitinib (Oral JAK1 Inhibitor)
Incyte Corporation
Why it matters: Patients interested in a potential first oral pill for HS. Prior biologic use permitted in some arms. Ask your dermatologist about access through extension studies.
BE HEARD Long-Term Extension - Bimekizumab (IL-17A/F Inhibitor)
UCB
Why it matters: Patients already treated with bimekizumab or interested in long-term durability data for this approved biologic.
Orismilast Phase 2 - Union Therapeutics (Oral PDE-4 Inhibitor)
Union Therapeutics
Why it matters: Patients interested in oral treatment options with a different mechanism than JAK inhibitors. Results expected late 2026.
INF904 Phase 2a - InflaRx (Oral C5aR1 Antagonist)
InflaRx
Why it matters: First complement inhibitor validated in HS. Early data showed mean reduction of 8.1 abscesses and nodules by week 4 at highest dose.